Jim Cramer said even tech-focused insiders favor Eli Lilly, with one predicting the drugmaker could eventually reach a $2 trillion market capitalization. Billionaire investor Ken Langone had predicted Lilly would top a $1 trillion market cap, which happened nearly a year ago; it now stands at a $1.2 trillion valuation. Lilly has emerged as the dominant GLP-1 player, and its shares closed at a record high above $1,306 on Oct. 22 before drifting lower. The CNBC Investing Club holds a hold-equivalent 2 rating on the stock, and Lilly is up 10.5% month-to-date versus 2.8% for the Dow, 0.3% for the S&P 500 and a 2.4% loss for the Nasdaq. Lilly reports third-quarter earnings Thursday, with investors watching growth in its weight-loss business, especially Foundayo.
Summary written by Upside AI from the original article. Read the source for full details.
Keywords
LLYpharmaceuticalsearningsvaluation
Open a keyword to see other news on the same topic.
Related news
- How Early Taltz and Zepbound Biomarker Synergies At Eli Lilly (LLY) Have Changed Its Investment Story
Eli Lilly's exploratory Phase 3b TOGETHER-PsO data showed that combining Taltz with Zepbound in adults with moderate-to-severe plaque psoriasis and obesity or overweight changed far more immune and metabolic biomarkers than Taltz alone, with broader responses emerging as early as Week 12. The findings point to a possible immunometabolic link between psoriasis and obesity, which could let Lilly pair its immunology and obesity portfolios. The article says the data does not materially change the near-term focus on obesity and diabetes volumes or the risks from GLP-1 pricing pressure and litigation. It also cites Phase 2b EloraTZP results combining eloralintide with tirzepatide. The article's investment narrative projects $118.9 billion in revenue and $50.1 billion in earnings by 2029, implying a fair value of $1,329, about 12% above the current price.
- 3 Portfolio-Worthy Stocks Hitting 52-Week Highs: AAPL, LLY & KO
Apple (AAPL), Eli Lilly (LLY) and Coca-Cola (KO) all reached new 52-week highs this week, representing technology growth, healthcare innovation and defensive consumer staples. Apple, near $350, is supported by renewed iPhone momentum and fiscal Q3 revenue of $109.41 billion (up 16%). Eli Lilly hit $1,321.21, driven by obesity and diabetes drugs; Q2 revenue rose 48% to $23 billion and full-year revenue guidance was raised to $85-$87 billion. Coca-Cola, near $95, pays a $2.12 annualized dividend with a 2.2% yield and has raised its dividend for 64 consecutive years. The article says valuations after recent rallies may warrant caution, but the three stocks have durable competitive advantages and are worth considering for long-term portfolios.
- Why Johnson & Johnson Stock Dropped Today
Johnson & Johnson shares fell 6.8% by 12:30 p.m. ET Tuesday despite beating third-quarter earnings expectations and raising 2026 guidance. Adjusted earnings were $2.59 per share against an expected $2.53, and sales grew 5.9%. However, adjusted profit fell 7.5% and GAAP profit dropped to $0.09 per share, down 96%, due to a one-time charge for the proposed talc litigation resolution and deals involving Firefly Bio and Sail Biomedicines. Free cash flow rose more than 6% to $15.1 billion, and the company now expects 2026 sales to grow 7.4% to $101.2 billion with adjusted earnings of about $11.10 per share. The author argues the stock's valuation of more than 22x adjusted earnings and nearly 29x free cash flow is too high for roughly 7% growth, and rates it a 'sell.'
- 3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist
The article argues that Pfizer, T. Rowe Price and Verizon look undervalued because the market is overreacting to their headwinds, while the S&P 500 trades at 23.5 times earnings with a 1.1% yield. Pfizer trades at 9.6 times forward earnings and offers a 5.6% dividend yield with a payout ratio just under 60%, though revenue and earnings have declined since 2022 and patent expirations such as Eliquis are pressuring shares. T. Rowe Price has a 5% forward dividend yield, a 40-year record of consecutive dividend growth and trades at 10 times forward earnings, and its pivot toward ETFs could soften the impact of a market downturn. Verizon added 550,000 net customer additions in mobility and broadband in the second quarter of 2026, but its shares have slumped on concerns about SpaceX's satellite services, and it has a 6.2% forward dividend yield at less than 9 times forward earnings.
- AstraZeneca offers compelling risk-reward into 2027 pipeline readouts, says JPMorgan
JPMorgan says AstraZeneca (LSE:AZN, NYSE:AZN) offers a compelling risk-reward opportunity ahead of late-stage readouts in 2027, which could collectively unlock more than $20 billion in non-risk-adjusted peak sales. Key studies include laroprovstat, Farxiga combinations, Datroway, puxi-sam, camizestrant and saruparib. The AVANZAR trial of Datroway has moved to Q1 2027 from Q4 2026 because progression-free survival events have not yet accumulated; JPMorgan says this could raise confidence in success, particularly in patients with the TROP2 biomarker. The stock trades at around 15 times 2027 earnings, broadly in line with European pharma, and the broker sees this as attractive given expected core earnings growth of around 10% over 2027-2030, roughly 40% ahead of the sector.
- ORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst Optimism
The modeled fair value for ORIC Pharmaceuticals moved from US$20.67 to US$21.93, a small change tied to analyst views on enozertinib and rinzimetostat. Several firms, including Stifel, JPMorgan and H.C. Wainwright, raised price targets into a US$18 to US$27 range, with JPMorgan describing enozertinib as an underappreciated driver. BTIG and Leerink initiated coverage with US$26 targets, while one analyst noted the stock was down 5% at US$12.89 in morning trading on the day of the lung cancer data update. The fair value model also changed the net profit margin assumption from 17.25% to 15.91% and the future P/E from 753.08x to 971.94x.
Related markets
Latest news
- Marvell Wants Lumentum. Here’s Why Coherent Could Win.
Bloomberg reported on October 28 that Marvell is in advanced discussions to acquire Lumentum, though no definitive agreement has been announced. Lumentum shares rose sharply on the news while Marvell fell in after-hours trading, and Coherent gained about 3.5% after hours. Per Bloomberg’s October 9 report, Lumentum’s optical capacity is effectively sold out through early 2029, and CEO Michael Hurlston said the company could not meet about 70% of expected demand for certain products through 2027. The article argues that a Marvell–Lumentum deal could make Coherent’s independent manufacturing more valuable, especially since Nvidia has invested $2 billion in Coherent.
- Google Cloud Revenue Just Grew 103%, so Why Is the Stock Falling?
Alphabet reported third-quarter results after the market close on Wednesday. Revenue rose 25% to $127.6 billion, below analyst estimates of $127.9 billion, while diluted EPS of $2.12 fell 26% against expectations of $3.01. Operating income climbed 30% to $40.6 billion. Google Cloud revenue soared 103% to $30.7 billion, with an operating margin of 36.2%, and CEO Sundar Pichai cited huge demand for AI infrastructure. The EPS decline mainly reflected an $8.2 billion loss on equity investments, including SpaceX, compared with gains of nearly $12.8 billion a year earlier. Alphabet expects capex of about $200 billion in 2026 and $300 billion in 2027, leaving free cash flow at -$9.1 billion, and the stock fell as much as 11% after hours.
- 2 Millionaire-Maker Custom Silicon Stocks Powering the AI Infrastructure Supercycle
The article profiles Broadcom and Taiwan Semiconductor Manufacturing (TSMC) as leading custom-silicon players. Broadcom, which partners with Alphabet on TPUs and counts Meta, OpenAI, and Anthropic among its ASIC customers, reported third-quarter AI semiconductor revenue up 221% to $16.7 billion and net income up roughly 216% to $13.1 billion. It expects fourth-quarter AI revenue to rise 236% to $21.7 billion, and the stock trades at about 28 times expected earnings this year. TSMC manufactures chips designed by its customers and, according to many estimates, controls over 90% of the high-end AI chip market. Its stock has delivered a total return of roughly 4,720% over 15 years. The author notes that both stocks' valuations have been volatile amid AI bubble concerns, while their market positions remain strong.
- Bel Fuse (BELFA) Stock Sees Modest Fair Value Lift As Analysts Rework Targets
Bel Fuse's estimated fair value has moved from US$313 to US$326, in line with recent Street targets of US$326 to US$335. Northland raised its target to US$326, calling it another strong quarter with a better-than-expected Q3 sales outlook. JPMorgan kept an Overweight rating but cut its target twice, most recently from US$380 to US$330 in October 2026, a more cautious stance on how current risks and execution uncertainties may cap valuation. Model assumptions were also updated: revenue growth from 11.53% to 11.94%, net profit margin from 20.57% to 20.35%, future P/E from 33.59x to 34.87x, and discount rate from 8.82% to 8.70%.
- 3 Founder Led Stocks With At Least 22% Earnings Growth
The article looks at three founder-led businesses as AI spending draws scrutiny after Alphabet reported negative free cash flow of US$9.07 billion and raised its AI infrastructure capex guidance. Sansan, a Japanese SaaS group founded by Chika Terada, generates about ¥48.9 billion from its Sansan and Bill One segment, with a market value near ¥273.9 billion. Spotify Technology, where Daniel Ek still shapes the long-term vision, earns about €18.8 billion in revenue, mostly from Premium subscriptions, and is valued near US$114.2 billion. China Medical System Holdings, controlled by Treasure Sea Limited, generates about CN¥7.3 billion from its Integrated Business and is valued near HK$24 billion. The article argues founder leadership may encourage more careful capital protection and highlights capital allocation and AI strategy as key questions for these companies.
- October 29: What to Read Before the Stock Market Opens
A roundup of domestic and international financial news from the past 24 hours. In Vietnam, Digiworld (DGW) reported third-quarter profit up 66% to VND 276 billion, though its shares still fell to the floor price, while Thế Giới Di Động (MWG) posted third-quarter net profit up 75% to nearly VND 3.1 trillion, and VIB reached nearly VND 7,600 billion in nine-month pre-tax profit, up 8%. Pi Group's PDCC repurchased VND 900 billion of bonds before maturity, spending nearly VND 996.3 billion. Globally, Beijing is urgently seeking to support its weakening stock market amid an AI sell-off, while the US pending home sales index fell 7.3% to 66.0 points in September 2026, its lowest since 2001.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.